Quetiapine augmentation of sertraline in obsessive-compulsive disorder [3]

Journal of Clinical Psychiatry

Volumn 63, Issue 11, 2002, Pages 1046-1047

  Francobandiera, Giorgio ^a  

^a ASL della Provincia di Sondrio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUVOXAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; TARDIVE DYSKINESIA;

EID: 0036855202     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1116d     Document Type: Letter

References (15)

1. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-43
2. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind placebo-controlled study in patients with or without tics. Arch Gen Psychiatry 1994;51:302-308
3. Stein DJ, Hollander E. Low dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992;53:123-126
4. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-654
5. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addiction in serotonin uptake inhibitors-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801
6. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series. J Clin Psychiatry 1999;60:524-527
7. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: An open study. Can J Psychiatry 2001;46:356-358
8. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): Case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001;26:55-59
9. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989;46:1006-1016
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
11. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51(8, suppl):36-43
12. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814
13. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [letter]. J Clin Psychopharmacol 1994;14:358-359
14. Morrison D, Clark D, Goldfirm GE, et al. Worsening of obsessive-compulsive symptoms following treatment with olanzapine [letter]. Am J Psychiatry 1998;155:855
15. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001;40:509-522